E-EYE IPL Treatment
Australian and New Zealand distributors for all optometric and opthalmic supplies and equipment. All your needs from Consulting Room Equipment to Vision Testing disposables and magnification solutions, Designs for Vision can help.
optometry, optometrist, opthalmology, opthalmologist, dentist, supplies, suplier, australia, sydney, melbourne, vision, Brisbane, New Zealand, testing, dentist, dentistry, consulting room, equipment, dental, surgical, sight testing, sight, surgical magnification, loupes, lenses, keeler, volk
product-template-default,single,single-product,postid-27345,theme-stockholm,stockholm-core-1.1,woocommerce,woocommerce-page,woocommerce-no-js,select-theme-ver-5.1.8,ajax_fade,page_not_loaded,wpb-js-composer js-comp-ver-6.0.5,vc_responsive

E-Eye is a device that generates polychromatic pulsed light pulses (Intense Pulsed Light, or IPL) to directly treat the Meibomian glands of patients diagnosed with dry eye disorders.

Meibomian Gland Dysfunction (MGD) is a major cause of dry eye discomfort. Treatment with E-Eye over several sessions can stimulate the function of these oil-producing glands, restoring the lipid layer of the ocular surface. The perfectly calibrated and homogenously sequenced light pulses of E-Eye are delivered in the form of regulated train pulses. The energy, spectrum and time period are precisely calculated to stimulate the meibomian glands.


Simple, fast and effective treatment

Treatment sessions take only a few minutes, are painless and non-invasive. The patient’s eyes are covered with a protective mask and a gel is applied to the cheekbones and temporal areas. A series of five flashes are applied to each eyelid per session. Stimulation of the meibomian glands may lead to improvements in a short time, with further improvements after follow-up treatment sessions.

E-Eye is manufactured in France by E-Swin and is the world’s most successful IPL treatment option for dry eye disorders. E-Eye has been supported with numerous clinical studies that have shown considerable improvement in the symptoms perceived by patients, with a 90% satisfaction rate after the first two treatments.